Breztri Aerosphere® is a long-term medicine to treat COPD and give patients better breathing, improve COPD symptoms and ...

AstraZeneca Pharma India rose 1.84% to Rs 6,515.50 after the durg maker said that it will launch Breztri Aerosphere in January 2025 in India.

This combination drug is used to treat chronic obstructive pulmonary disease in adults, relieving symptoms and preventing ...

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

The combination medication is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to ...

The pharma major wants to bring innovative medicines to India faster, while increasing the access to its mass-market products ...

Inhaler previously announced the details of their new album alongside their biggest ever UK tour. The Dublin four-piece will release their third studio effort Open Wide on 7th February and will ...

Get detailed information on Budesonide, including pronunciation ... Maintenance: 6 mg once daily, up to 3 months. Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China. The decrease marked ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

LONDON, Nov 4 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and ...

AstraZeneca and Eccogene presented early data from trials on ECC5004 for obesity, showing consistent safety and tolerability. In trials, ECC5004 displayed a linear PK profile and was unaffected by ...